BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,040

Employees3,040

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,040

Employees3,040

BMRN Key Statistics

Market cap

10.94B

Market cap10.94B

Price-Earnings ratio

21.35

Price-Earnings ratio21.35

Dividend yield

—

Dividend yield—

Average volume

2.03M

Average volume2.03M

High today

$57.04

High today$57.04

Low today

$55.80

Low today$55.80

Open price

$56.27

Open price$56.27

Volume

2.19M

Volume2.19M

52 Week high

$73.51

52 Week high$73.51

52 Week low

$50.76

52 Week low$50.76

Stock Snapshot

The current BioMarin(BMRN) stock price is $56.99, with a market capitalization of 10.94B. The stock trades at a price-to-earnings (P/E) ratio of 21.35.

As of 2026-01-30, BioMarin(BMRN) stock has fluctuated between $55.80 and $57.04. The current price stands at $56.99, placing the stock +2.1% above today's low and -0.1% off the high.

The BioMarin(BMRN)'s current trading volume is 2.19M, compared to an average daily volume of 2.03M.

During the past year, BioMarin(BMRN) stock moved between $50.76 at its lowest and $73.51 at its peak.

BMRN News

Simply Wall St 48m

Does Strong Financials And Rare-Disease Partnerships Change The Bull Case For Catalyst Pharmaceuticals?

In recent days, Catalyst Pharmaceuticals has been highlighted for strong earnings and revenue growth, solid profitability, and a debt-free balance sheet, earnin...

TipRanks 13h

BioMarin Secures Major Debt Financing for Amicus Acquisition

BioMarin Pharmaceutical ( (BMRN) ) just unveiled an announcement. On January 29, 2026, BioMarin Pharmaceutical Inc. priced a private offering of $850 million i...

Simply Wall St 1d

BioMarin Weighs Amicus Deal And Billions In New Debt Financing

BioMarin Pharmaceutical, ticker NasdaqGS:BMRN, has announced plans to acquire Amicus Therapeutics, adding approved rare disease therapies such as Galafold and P...

Analyst ratings

78%

of 27 ratings

Buy

77.8%

Hold

22.2%

Sell

More BMRN News

TipRanks 3d

BioMarin assumed with an Overweight at Barclays

Barclays assumed coverage of BioMarin (BMRN) with an Overweight rating and $80 price target Barclays initiated coverage of 12 biotech stocks and assumed coverag...

Simply Wall St 3d

Assessing BioMarin Pharmaceutical Valuation As Investors Revisit The Rare Disease Specialist

Advertisement Why BioMarin Pharmaceutical Is Back on Investor Radars BioMarin Pharmaceutical (BMRN) has drawn fresh attention after recent share price swings,...

Nasdaq 4d

BioMarin To Raise $850 Mln In Sr. Notes To Fund Amicus Acquisition

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN), announced on Monday its plans to offer $850 million in senior unsecured notes due 2034. The company also launc...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.